Perspective Therapeutics to Participate in Upcoming Investor Conferences in November
Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focusing on cancer treatments, has announced its participation in four major investor conferences this November. The company will attend the Truist Securities BioPharma Symposium (Nov 7) in New York for one-on-one meetings, the UBS Global Healthcare Conference (Nov 13) in California featuring a fireside chat, the Stifel Healthcare Conference (Nov 18) in New York with a fireside chat, and the Jefferies London Healthcare Conference (Nov 19-21) for one-on-one meetings. Webcasts of applicable events will be available live and archived for 90 days on the company's investor website.
Perspective Therapeutics (NYSE AMERICAN: CATX), una compagnia di radioterapici focalizzata sui trattamenti per il cancro, ha annunciato la sua partecipazione a quattro importanti conferenze per investitori questo novembre. L'azienda parteciperà al Truist Securities BioPharma Symposium (7 novembre) a New York per incontri individuali, al UBS Global Healthcare Conference (13 novembre) in California con un incontro informale, al Stifel Healthcare Conference (18 novembre) a New York con un incontro informale e al Jefferies London Healthcare Conference (19-21 novembre) per incontri individuali. Le trasmissioni degli eventi pertinenti saranno disponibili in diretta e archiviate per 90 giorni sul sito web per investitori dell'azienda.
Perspective Therapeutics (NYSE AMERICAN: CATX), una empresa de radiofármacos enfocada en tratamientos contra el cáncer, ha anunciado su participación en cuatro importantes conferencias para inversores este noviembre. La compañía asistirá al Truist Securities BioPharma Symposium (7 de noviembre) en Nueva York para reuniones individuales, a la UBS Global Healthcare Conference (13 de noviembre) en California con una charla junto a la chimenea, a la Stifel Healthcare Conference (18 de noviembre) en Nueva York con una charla junto a la chimenea, y a la Jefferies London Healthcare Conference (19-21 de noviembre) para reuniones individuales. Las transmisiones de los eventos pertinentes estarán disponibles en vivo y archivadas por 90 días en el sitio web para inversores de la compañía.
Perspective Therapeutics (NYSE AMERICAN: CATX), 암 치료에 중점을 둔 방사성 의약품 회사는 이번 11월에 열리는 네 가지 주요 투자자 회의에 참석할 것이라고 발표했습니다. 이 회사는 뉴욕에서 열리는 Truist Securities BioPharma Symposium (11월 7일) 1:1 미팅에 참석하고, 캘리포니아에서 열리는 UBS Global Healthcare Conference (11월 13일)에서는 허닷룸 대화를 진행하며, 뉴욕의 Stifel Healthcare Conference (11월 18일)에서도 허닷룸 대화를 갖고, Jefferies London Healthcare Conference (11월 19-21일)에서는 1:1 미팅을 진행합니다. 관련 이벤트의 웹캐스트는 생중계되며 회사의 투자자 웹사이트에서 90일 동안 архив됩니다.
Perspective Therapeutics (NYSE AMERICAN: CATX), une entreprise de radiopharmaceutiques axée sur les traitements anticancéreux, a annoncé sa participation à quatre grandes conférences d'investisseurs en novembre. L'entreprise assistera au Truist Securities BioPharma Symposium (7 novembre) à New York pour des réunions individuelles, à la UBS Global Healthcare Conference (13 novembre) en Californie avec une discussion autour du feu de camp, à la Stifel Healthcare Conference (18 novembre) à New York avec une discussion autour du feu de camp, et à la Jefferies London Healthcare Conference (19-21 novembre) pour des réunions individuelles. Les webcasts des événements pertinents seront disponibles en direct et archivés pendant 90 jours sur le site web des investisseurs de l'entreprise.
Perspective Therapeutics (NYSE AMERICAN: CATX), ein Unternehmen für Radiopharmazeutika, das sich auf Behandlungen gegen Krebs konzentriert, hat seine Teilnahme an vier wichtigen Investorenkonferenzen im November angekündigt. Das Unternehmen wird am Truist Securities BioPharma Symposium (7. November) in New York für persönliche Treffen teilnehmen, an der UBS Global Healthcare Conference (13. November) in Kalifornien, die ein informelles Gespräch beinhaltet, an der Stifel Healthcare Conference (18. November) in New York mit einem informellen Gespräch und an der Jefferies London Healthcare Conference (19.-21. November) für persönliche Treffen teilnehmen. Webcasts der relevanten Veranstaltungen werden live übertragen und für 90 Tage auf der Investorenseite des Unternehmens archiviert.
- None.
- None.
SEATTLE, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.
Truist Securities BioPharma Symposium
Date: November 7, 2024
Location: Lotte New York Palace - New York, NY
Format: 1x1 meetings only
UBS Global Healthcare Conference
Date: November 13, 2024
Location: Rancho Palos Verdes, CA
Format: Fireside Chat
Time: 2:45 p.m. – 3:20 p.m. PT / 5:45 p.m. – 6:20 p.m. ET
Stifel 2024 Healthcare Conference
Date: November 18, 2024
Location: New York, NY
Format: Fireside Chat
Time: 9:10 a.m. – 9:40 a.m. ET
Jefferies London Healthcare Conference
Date: November 19-21, 2024
Location: London, UK
Format: 1x1 meetings only
Webcast events can be accessed live, and replays will be archived for 90 days and available through the Investors page on the Perspective website at https://perspectivetherapeutics.com/investor-center.
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary 212Pb generator to secure key isotopes for clinical trial and commercial operations.
For more information, please visit the Company's website at www.perspectivetherapeutics.com.
FAQ
What investor conferences will Perspective Therapeutics (CATX) attend in November 2024?
Where can I watch the webcasts of Perspective Therapeutics (CATX) conference presentations?